The stock of Nantkwest Inc (NASDAQ:NK) is a huge mover today! About 108,596 shares traded hands. Nantkwest Inc (NASDAQ:NK) has declined 17.11% since March 9, 2016 and is downtrending. It has underperformed by 24.53% the S&P500.
The move comes after 9 months negative chart setup for the $556.09M company. It was reported on Oct, 12 by Barchart.com. We have $6.57 PT which if reached, will make NASDAQ:NK worth $27.80 million less.
Analysts await Nantkwest Inc (NASDAQ:NK) to report earnings on November, 10. They expect $-0.38 earnings per share, up 30.91% or $0.17 from last year’s $-0.55 per share. After $-0.41 actual earnings per share reported by Nantkwest Inc for the previous quarter, Wall Street now forecasts -7.32% EPS growth.
Nantkwest Inc (NASDAQ:NK) Ratings Coverage
Out of 7 analysts covering NantKwest (NASDAQ:NK), 5 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 71% are positive. NantKwest has been the topic of 8 analyst reports since August 24, 2015 according to StockzIntelligence Inc. The stock of Nantkwest Inc (NASDAQ:NK) has “Buy” rating given on Tuesday, December 22 by Canaccord Genuity. As per Monday, August 24, the company rating was initiated by Jefferies. The firm has “Buy” rating by Citigroup given on Monday, August 24. MLV initiated Nantkwest Inc (NASDAQ:NK) on Monday, August 24 with “Buy” rating. The rating was initiated by Piper Jaffray with “Overweight” on Monday, August 24. The rating was initiated by FBR Capital with “Outperform” on Wednesday, October 28. Citigroup maintained the stock with “Neutral” rating in Monday, March 14 report. The firm has “Market Perform” rating by Raymond James given on Thursday, June 2.
According to Zacks Investment Research, “NantKwest, Inc. is a clinical-stage immunotherapy company. The Company’s product candidates include aNK, haNK and taNK for the treatment of cancers, infectious and inflammatory diseases. It is focused on harnessing the power of the innate immune system by using the natural killer cell. NantKwest, Inc. is headquartered in Cardiff-by-the-Sea, California.”
More notable recent Nantkwest Inc (NASDAQ:NK) news were published by: Fool.com which released: “Better Buy: NantKwest, Inc. vs. Ionis Pharmaceuticals” on June 28, 2016, also Fool.com with their article: “Why NantKwest, Inc.’s Shares Briefly Stumbled Today” published on March 11, 2016, Latimes.com published: “LA billionaire Soon-Shiong gets $148-million payday even as his firm’s stock tanks” on April 28, 2016. More interesting news about Nantkwest Inc (NASDAQ:NK) were released by: Wsj.com and their article: “NantKwest Gives Biotech Another Big IPO” published on July 28, 2015 as well as Businesswire.com‘s news article titled: “NantKwest Augments, Strengthens Senior Management Team” with publication date: September 22, 2015.
NK Company Profile
NantKwest, Inc., formerly Conkwest, Inc., incorporated on March 12, 2014, is a biotechnology company, which is engaged in developing targeted direct-acting immunotherapeutic agents for a range of clinical conditions. The Firm is a clinical-stage immunotherapy firm focused on harnessing its immune system by using the natural killer (NK) cell to treat cancer, infectious diseases and inflammatory diseases. The Company’s NK cell platform, with the capacity to grow active killer cells as a biological cancer therapy, has been designed to induce cell death against cancer or infected cells by three different modes of action, such as direct killing using activated NK cells (aNK) that release toxic granules directly into the cell through cell to cell contact; antibody-mediated killing using high-affinity NKs (haNKs), which are NK cells engineered to incorporate a high affinity receptor that binds to an administered antibody, enhancing the cancer cell killing effect of that antibody, and targeted activated killing using target activated Natural Killers (taNKs), which are NK cells engineered to incorporate chimeric antigen receptors (CARs) to target tumor-specific antigens found on the surface of cancer cells.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.